NIFTY 50 23203.2 ▼ (0.47%)
NIFTY NEXT 50 65053.6 ▲ (0.76%)
NIFTY 100 23926 ▼ (0.24%)
NIFTY MIDCAP 100 54607.65 ▲ (0.23%)
NIFTY SMALLCAP 100 17672.05 ▲ (0.16%)
NIFTY SMALLCAP 250 16700.5 ▼ (0.04%)
NIFTY MIDCAP SELECT 12249.85 ▲ (0.26%)
NIFTY TOTAL MARKET 12230.75 ▼ (0.15%)
NIFTY BANK 48540.6 ▼ (1.5%)
SENSEX 76619.33 ▼ (0.55%)
BSE BANKEX 54919.15 ▼ (1.83%)

Link Pharma Chem : Q4 2024 Financial Quarterly Report : YoY Sales Down 13.55 %, QoQ Up 1.17 %

July 1, 2024July 1, 2024| adminadmin| 0 Comments| 12:40 pm
Image is loading
Categories:

Share the post "Link Pharma Chem : Q4 2024 Financial Quarterly Report : YoY Sales Down 13.55 %, QoQ Up 1.17 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company’s sales declined by -13.55 % over the year, substantial increase in net sales/revenue by 1.17 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 50 %. Marginal decrease of -102.7% in other income during this quarter.
  • Profit over the Year and quarter: Challenges in sustaining profitability for Link Pharma Chem Ltd.. Profit dropped by -234.72 % Year to Year, Link Pharma Chem Ltd.’s profitability increased by 17.65 % in this quarter.
  • EPS over the Year and quarter: EPS declined by -234.09 % Year to Year. EPS increased by 18 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Link Pharma Chem Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 9.291 Cr Rs. 7.939 Cr Rs. 8.032 Cr + 1.17 % -13.55 %
Expenses Rs. 9.01 Cr Rs. 7.66 Cr Rs. 7.11 Cr -7.18 % -21.09 %
Operating Profit Rs. 0.28 Cr Rs. 0.28 Cr Rs. 0.92 Cr + 228.57 % + 228.57 %
OPM % 3.01 % 3.53 % 11.45 % + 7.92 % + 8.44 %
Other Income Rs. -0.02 Cr Rs. 0.37 Cr Rs. -0.01 Cr -102.7 % + 50 %
Interest Rs. 0.26 Cr Rs. 0.23 Cr Rs. 0.2 Cr -13.04 % -23.08 %
Depreciation Rs. 0.23 Cr Rs. 0.27 Cr Rs. 0.25 Cr -7.41 % + 8.7 %
Profit before tax Rs. -0.23 Cr Rs. 0.15 Cr Rs. 0.46 Cr + 206.67 % + 300 %
Tax % -17.52 % 45.39 % 44.21 % -1.18 % + 61.73 %
Net Profit Rs. -0.19 Cr Rs. 0.22 Cr Rs. 0.26 Cr + 18.18 % + 236.84 %
EPS in Rs Rs. -0.44 Rs. 0.5 Rs. 0.59 + 18 % + 234.09 %


Today, we’re looking at Link Pharma Chem Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -13.55 %. However, it did see a marginal increase of 1.17 % from the previous quarter. Expenses decreased slightly by -7.18 % quarter-on-quarter, aligning with the annual decline of -21.09 %. Operating profit, while up 228.57 % compared to last year, faced a quarter-on-quarter increase of 228.57 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 8.44 %, but an expansion of 7.92 % sequentially. Other income fell by -102.7 % compared to the last quarter, despite an annual growth of 50 %. Interest expenses dropped significantly by -13.04 % from the previous quarter, yet the year-over-year decrease remains at a moderate -23.08 %. Depreciation costs fell by -7.41 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 8.7 %. Profit before tax grew annually by 300 % but saw an increase from the preceding quarter by 206.67 %.
Tax expenses as a percentage of profits increased slightly by 61.73 % compared to last year, with a more notable quarter-on-quarter decrease of -1.18 %. Net profit rose by 236.84 % year-on-year but experienced a 18.18 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 234.09 % but a quarterly rise of 18 %. In summary, Link Pharma Chem Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 9.291 Cr Rs. 7.939 Cr Rs. 8.032 Cr + 1.17 % -13.55 %
Expenses Rs. 9.01 Cr Rs. 7.66 Cr Rs. 7.11 Cr -7.18 % -21.09 %
Operating Profit Rs. 0.28 Cr Rs. 0.28 Cr Rs. 0.92 Cr + 228.57 % + 228.57 %
Net Profit Rs. -0.19 Cr Rs. 0.22 Cr Rs. 0.26 Cr + 18.18 % + 236.84 %
EPS in Rs Rs. -0.44 Rs. 0.5 Rs. 0.59 + 18 % + 234.09 %


In reviewing Link Pharma Chem Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -13.55 % year-on-year, however, there was a minor increase of 1.17 % from the previous quarter. Expenses decreased by -21.09 % compared to the previous year, with a decrease of -7.18 % quarter-on-quarter. Operating Profit surged by 228.57 % annually, and saw a 228.57 % increase from the last quarter.
Net Profit showed yearly increase of 236.84 %, and experienced a 18.18 % increase from the previous quarter. Earnings Per Share (EPS) rose by 234.09 % annually, however rose by 18 % compared to the last quarter. In essence, while Link Pharma Chem Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Link Pharma Chem “]

Related Post